A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
A phase 2 trial of ABSK043 in combination with Firmonertinib in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib is a phase 2 interventional study registered as NCT06668103 by Abbisko Therapeutics Co, Ltd, with 54 participants planned, started 2024-11-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: ABSK043 in combination with Firmonertinib.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Shares Abbisko Therapeutics and the tag pipeline.
- TrialABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Shares Abbisko Therapeutics and the tag pipeline.
- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Abbisko Therapeutics and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.